PolyPidPYPD
About: PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
Employees: 62
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
33% more funds holding
Funds holding: 9 [Q2] → 12 (+3) [Q3]
28% more capital invested
Capital invested by funds: $5.19M [Q2] → $6.64M (+$1.46M) [Q3]
14.88% more ownership
Funds ownership: 25.17% [Q2] → 40.05% (+14.88%) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Craig-Hallum Chase Knickerbocker 43% 1-year accuracy 10 / 23 met price target | 178%upside $10 | Buy Initiated | 4 Nov 2024 |
HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 111 / 295 met price target | 289%upside $14 | Buy Reiterated | 2 Oct 2024 |
Financial journalist opinion
Based on 4 articles about PYPD published over the past 30 days
